We used the LRC-TriCEPS technology from Dualsystems to identify interacting proteins for a tumor-secreted factor on the surface of differentiated myotubes. The main interaction partner identified through the LRC-TriCEPS workflow could be confirmed using independent experimental methods. This discovery proved pivotal for elucidating the underlying mechanism of action responsible for the phenotypic effects we had observed and facilitated further development toward specific therapeutic targeting. We highly appreciated the professional and dedicated support provided by the Dualsystems team throughout the project, which contributed to the smooth and successful execution of the study. Dr. Mauricio Berriel Diaz Deputy Director & Head of Division Metabolism and Cancer Institute for Diabetes and Cancer (IDC) www.helmholtz-munich.de